Because SMAD4 mutated or deleted pancreatic cancers have an increased reliance on autophagy for treatment resistance, we hypothesized that patients with SMAD4 tumor loss/mutation would derive the greatest benefit from autophagy inhibition with HCQ. The gene discussed is SMAD4; the disease is familial pancreatic carcinoma.